Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The increasing use of MRD to personalize therapy for multiple myeloma in clinical practice

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the use of measurable residual disease (MRD) to personalize therapy for patients with multiple myeloma, mentioning key clinical trials including RADAR (ISRCTN46841867; UK-MRA Myeloma XV), and explaining how MRD status may be used in the future to de-escalate therapy, define duration of maintenance therapy, initiate treatment before disease relapse, and to change treatment for high-risk patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda, Bristol Myers Squibb, Janssen, Amgen, GlaxoSmithKline: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel, Research Funding, Speakers Bureau; Sanofi, Adaptive biotech, Oncopeptides: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.